'Other' targets in lung cancer

Developments in gastrointestinal tumour treatment

Modern antiematogenic therapy from 5-HT3 to NK-1 antagonists

Towards deciphering the functional genetics and neo-antigenic landscape in melanoma

Polycomb repressors and epigenetic therapy

DNA repair and mutations as targets for personalised therapy

The changing process of drug discovery and design

Glioblastoma heterogeneity in circulating tumour DNA

Obesity promotes pancreatic cancer progression and resistance

Connections in cancer-host immune signalling

Targeting and imaging invasion and metastasis

ERß expression predicts breast cancer risk in hyperplasia